Here’s what you should know:
1. SeaSpine’s U.S. revenues increased 8 percent year over year to $32 million.
2. The company’s U.S. orthobiologics division increased revenues 8 percent to $17 million, with the spinal implant division posting $14.9 million in revenues, a 9 percent year-over-year increase.
3. The recently launched Shoreline and Mariner systems and the company’s expanded NanoMetalene portfolio contributed to the spinal implant division’s growth.
4.The company posted net losses of $9 million for the quarter, up from $7.1 million last year.
5. SeaSpine’s full-year outlook increased to $154 million to $156 million.
More articles on devices:
Healthcare experts discuss investor interest in orthopedics — 5 key points
University of Maryland children’s medical device competition reveals 5 winners
RTI Surgical reports $9.1M net loss in Q1: 5 details
